Overview

Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers

Status:
Not yet recruiting

Trial end date:
2029-04-01

Target enrollment:

Participant gender:

Summary

IMGN853-0421 is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of Mirvetuximab Soravtansine in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.

Phase:

Phase 3

Details

Lead Sponsor:

ImmunoGen, Inc.

Treatments:

Bevacizumab
Maytansine